Cyclopropanes

MerLion Pharmaceuticals Completes Growth Financing Round

Retrieved on: 
Tuesday, May 18, 2021
Fluoroquinolone antibiotics, Chemical compounds, Drugs, Chemistry, Cyclopropanes, Finafloxacin, Nitriles, Otologicals, Ofloxacin, Quinolone antibiotic, Otitis externa, Merlion

\xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.

Key Points: 
  • \xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.
  • Its superior, fast acting properties will aid patients considerably in their recovery.\xe2\x80\x9d\nMerLion Pharmaceuticals GmbH is a is a privately held company biopharmaceutical company headquartered in Berlin, Germany.
  • MerLion is supported by a group of leading global investors.
  • For more information, please visit http://www.merlionpharma.com\nPOELLATH, Munich, Dr. Michael Inhester and Adalbert Makos advised MerLion on the investment and capital raise.\nFinafloxacin is a novel fluoroquinolone antibiotic with best-in-class features.

Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Retrieved on: 
Tuesday, May 11, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Anatomy, Companies, Branches of biology, Ipsen, Cyclopropanes, Orphan drugs, Cabozantinib, Exelixis, Thyroid cancer, Takeda Pharmaceutical Company, Thyroid, radioiodine-refractory differentiated thyroid cancer, the COSMIC-311 trial, Cabometyx (cabozantinib), Ipsen, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER, THE COSMIC-311 TRIAL, CABOMETYX (CABOZANTINIB), IPSEN

Cabometyx is marketed by Exelixis in the U.S. and by Takeda Pharmaceutical Company Limited in Japan.

Key Points: 
  • Cabometyx is marketed by Exelixis in the U.S. and by Takeda Pharmaceutical Company Limited in Japan.
  • Cabometyx is a registered trademark of Exelixis.\nIpsen is a global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
  • For more information on Ipsen, visit www.ipsen.com\nThe forward-looking statements, objectives and targets contained herein are based on the Group\xe2\x80\x99s management strategy, current views and assumptions.
  • Oncol Lett 19: 1985-1992, 2020. doi: 10.3892/ol.2020.11304.\nWorden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Quinolines, Cyclopropanes, Tyrosine kinase inhibitors, Cabozantinib, Ipsen, Exelixis, Drugs, Asco, Clinical medicine, Health care

In February 2021, cabozantinib was the subject of multiple data presentations at ASCO GU 2021, held virtually from February 11-13.

Key Points: 
  • In February 2021, cabozantinib was the subject of multiple data presentations at ASCO GU 2021, held virtually from February 11-13.
  • In March 2021, Exelixis announced its partner Ipsen received approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC.
  • Exelixis in-licensed XB002 from Iconic Therapeutics, Inc. in December 2020 under the companies\xe2\x80\x99 May 2019 collaboration agreement.\nExelixis Outlines Key Priorities and Anticipated Milestones for 2021.
  • In March 2021, Exelixis announced an exclusive license agreement with WuXi Bio to support the continued expansion of Exelixis\xe2\x80\x99 oncology biologics pipeline.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Cyclopropanes, Quinolines, Tyrosine kinase inhibitors, Cabozantinib, Exelixis, Cobimetinib, Midcap, Trademark

Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline.

Key Points: 
  • Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline.
  • Exelixis is a member of the Standard & Poor\xe2\x80\x99s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.\nExelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.
  • MINNEBRO is a registered Japanese trademark.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427006099/en/\n'

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Retrieved on: 
Tuesday, April 27, 2021
Glaucoma, NicOx, Chemical compounds, Organ systems, Blindness, Vision, Ophthalmology, Cyclopropanes, Ocular hypertension, Intraocular pressure, Normal tension glaucoma, Latanoprost

b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma.

Key Points: 
  • b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma.
  • Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA\xc2\xae, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.\nNormal tension glaucoma, also known as low tension or normal pressure glaucoma, is a form of glaucoma in which damage occurs to the optic nerve at intraocular pressure (IOP) within the normal range (less than 21 mmHg).
  • Nicox\xe2\x80\x99s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.
  • The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.

Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 22, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Cobimetinib, NASDAQ

b'Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close.

Key Points: 
  • b'Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • Exelixis is a member of the Standard & Poor\xe2\x80\x99s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.\nExelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

Retrieved on: 
Monday, April 19, 2021
Chemical compounds, Medical specialties, Surgery, Alcohols, Cyclopropanes, Ticagrelor, Surgical specialties, Cardiac surgery, Rivaroxaban, Cardiothoracic surgery

The Company has already identified and pre-screened many high-quality U.S. clinical centers that have indicated strong interest to participate in the STAR-T trial.

Key Points: 
  • The Company has already identified and pre-screened many high-quality U.S. clinical centers that have indicated strong interest to participate in the STAR-T trial.
  • David Cox, Vice President of Global Regulatory of CytoSorbents stated, "We are pleased that the FDA has approved our randomized, controlled clinical trial for the removal of ticagrelor (Brilinta,AstraZeneca) during cardiothoracic surgery to reduce perioperative bleeding complications.
  • "\nIn April 2020, the FDA granted CytoSorbents Breakthrough Device Designation to remove ticagrelor during cardiothoracic surgery, recognizing this major unmet medical need.
  • CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor and rivaroxaban during cardiothoracic surgery.

BioCorRx Provides 2020 Year-End Business Update

Retrieved on: 
Thursday, April 1, 2021
Alcohol abuse, Chemical compounds, Organic compounds, Psychoactive drugs, Substance dependence, Abnormal psychology, Cyclopropanes, Ethers, Naltrexone, Addiction, Opioid, Drug rehabilitation

ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --BioCorRx Inc. (OTCQB: BICX) (the Company),a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --BioCorRx Inc. (OTCQB: BICX) (the Company),a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, We are very pleased with the clinical and corporate progress we made during 2020.
  • Despite the COVID-19 pandemic, our subsidiary, BioCorRx Pharmaceuticals Inc., has advanced our pivotal good laboratory practice (GLP) preclinical studies of our sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
  • BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Retrieved on: 
Wednesday, March 31, 2021
Oncology, Health, FDA, Other Health, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Drugs, Antineoplastic drugs, Cancer treatments, Cabozantinib, Cyclopropanes, Quinolines, Ipsen, Nivolumab, Sunitinib, Renal cell carcinoma, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX (cabozantinib) in combination with OPDIVO (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX (cabozantinib) in combination with OPDIVO (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC).
  • CheckMate -9ER is an open-label, randomized (1:1), multi-national phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma with a clear cell component.
  • The primary efficacy analysis compares the doublet combination regimen of CABOMETYX and OPDIVO versus sunitinib in all randomized patients.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Retrieved on: 
Tuesday, March 23, 2021
Orphan drugs, Chemical compounds, Organic compounds, Drugs, Chloroarenes, Ureas, Protein kinase inhibitors, Cyclopropanes, Lenvatinib, Merck & Co., Eisai, Thymic carcinoma

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.